Expression of Multidrug Resistance (MDR) Associated P-glycoprotein of Acute Lymphoblastic Leukemia in Children.
- Author:
Yoon Jung CHOI
1
;
Chan Uk U
;
Jung Hwa LEE
;
Kwang Chul LEE
;
Soon Kyum KIM
;
Sul Ee PARK
Author Information
1. Major in Pediatrics, Department of Medical Science, Korea University, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Acute lymphoblastic leukemia;
Multidrug resistance associated P-glycoprotein
- MeSH:
Bone Marrow;
Child*;
Diagnosis;
Disease-Free Survival;
Drug Resistance, Multiple*;
Humans;
P-Glycoprotein*;
Precursor Cell Lymphoblastic Leukemia-Lymphoma*;
Prognosis;
Prospective Studies;
Recurrence;
Sex Ratio;
Survival Rate
- From:Korean Journal of Pediatric Hematology-Oncology
1999;6(1):39-47
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To evaluate the association between multidrug resistance (MDR) gene and prognosis of acute lymphoblastic leukemia (ALL), several parameters were compared according to the expression status of MDR associated P-glycoprotein. METHODS: 40 bone marrow samples from 36 children of acute lymphoblastic leukemia were analyzed with immunohistochemical stain by C219 monoclonal antibody. RESULTS: 1) The expression of MDR associated P-glycoprotein was positive in 47% at the time of initial diagnosis & 66.7% at relapse. 2) There are no stastical difference between two groups in complete remission rate, relapse rate, mean 2 years survival rate. 3) Event free survival duration was 11.3 months (+/-8.5 months) in P-glycoprotein positive group, while 20 months (+/-7.3months) in P-glycoprotein negative group (P<0.05). 4) There are no stastical difference between two groups in the mean age, sex ratio, initial WBC and immunophenotype of subjects. CONCLUSION: These results suggested the possibility of adopting MDR associated P-glycoprotein in the design of therapeutic regimen and prognostification of childhood acute lymphoblastic leukemia. However, a prospective, randomized study incorporating a larger population should precede before a firm conclusion of significance would draw regarding the prognostic and the therapeutic implication of P-glycoprotein in childhood acute lymphoblastic leukemia.
